Advertisement

Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction

      Abstract

      Large clinical trials demonstrate that control of blood pressure or hyperlipidemia reduces risk for cardiovascular events by ∼30%. Factors that may further reduce remaining risk are not definitively established. One potential target is atherosclerosis, a crucial feature in the pathogenesis of cardiovascular diseases whose development is determined by multiple mechanism including complex interactions between endothelial dysfunction and insulin resistance. Reciprocal relationships between endothelial dysfunction and insulin resistance as well as cross-talk between hyperlipidemia and the rennin–angiotensin–aldosterone system may contribute to development of atherosclerosis. Therefore, one appealing strategy for prevention or treatment of atherosclerosis may be to simultaneously address several risk factors with combination therapies that target multiple pathogenic mechanisms. Combination therapy with statins, peroxisome proliferators-activated receptor agonists, and rennin–angiotensin–aldosterone system blockers demonstrate additive beneficial effects on endothelial dysfunction and insulin resistance when compared with monotherapies in patients with cardiovascular risk factors. Additive beneficial effects of combined therapy are mediated by both distinct and interrelated mechanisms, consistent with both pre-clinical and clinical investigations. Thus, combination therapy may be an important concept in developing more effective strategies to treat and prevent atherosclerosis, coronary heart disease, and co-morbid metabolic disorders characterized by endothelial dysfunction and insulin resistance.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Koh K.K.
        Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
        Cardiovasc Res. 2000; 47: 648-657
        • Kim J.
        • Montagnani M.
        • Koh K.K.
        • Quon M.J.
        Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.
        Circulation. 2006; 113: 1888-1904
        • Kim J.A.
        • Koh K.K.
        • Quon M.J.
        The union of vascular and metabolic actions of insulin in sickness and in health.
        Arterioscler Thromb Vasc Biol. 2005; 25: 889-891
        • Koh K.K.
        • Han S.H.
        • Quon M.J.
        Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.
        J Am Coll Cardiol. 2005; 46: 1978-1985
        • Han S.H.
        • Quon M.J.
        • Kim J.
        • Koh K.K.
        Adiponectin and cardiovascular disease: response to therapeutic interventions.
        J Am Coll Cardiol. 2007; 49: 531-538
        • Koh K.K.
        • Quon M.J.
        Targeting converging therapeutic pathways to overcome hypertension.
        Int J Cardiol. 2009; 132: 297-299
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • et al.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
        N Engl J Med. 2000; 342: 145-153
        • HOPE/HOPE-TOO Study Investigators
        Long-term effects of ramipril on cardiovascular events and on diabetes results of the HOPE Study Extension.
        Circulation. 2005; 112: 1339-1346
        • Dahlöf B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • et al.
        Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • Koh K.K.
        • Ahn J.Y.
        • Han S.H.
        • et al.
        Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
        J Am Coll Cardiol. 2003; 42: 905-910
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
        Int J Cardiol. 2006; 108: 96-100
        • Ciulla M.M.
        • Paliotti R.
        • Esposito A.
        • et al.
        Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
        Circulation. 2004; 110: 552-557
        • Diez J.
        • Querejeta R.
        • Lopez B.
        • et al.
        Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.
        Circulation. 2002; 105: 2512-2517
        • Schiffrin E.L.
        • Park J.B.
        • Intengan H.D.
        • Touyz R.M.
        Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
        Circulation. 2000; 101: 1653-1659
        • Yasunari K.
        • Maeda K.
        • Watanabe T.
        • et al.
        Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
        J Am Coll Cardiol. 2004; 43: 2116-2123
        • Cutler J.A.
        • Davis B.R.
        Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.
        Circulation. 2008; 117: 2691-2704
        • Messerli F.H.
        • Bangalore S.
        • Julius S.
        Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension.
        Circulation. 2008; 117: 2706-2715
        • Gurwitz J.H.
        • Bohn R.L.
        • Glynn R.J.
        • et al.
        Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus.
        Ann Intern Med. 1993; 118: 273-278
        • Yusuf S.
        • Ostergren J.B.
        • Gerstein H.C.
        • et al.
        Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
        Circulation. 2005; 112: 48-53
        • Julius S.
        • Kjeldsen S.E.
        • Weber M.
        • et al.
        Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
        Lancet. 2004; 363: 2022-2031
        • DREAM Trial Investigators
        • Bosch J.
        • Yusuf S.
        • et al.
        Effect of ramipril on the incidence of diabetes.
        N Engl J Med. 2006; 355: 1551-1562
        • Eriksson J.W.
        • Jansson P.A.
        • Carlberg B.
        • et al.
        Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
        Hypertension. 2008; 52: 1030-1037
        • Sjöstrand M.
        • Eriksson J.W.
        Neuroendocrine mechanisms in insulin resistance.
        Mol Cell Endocrinol. 2009; 297: 104-111
        • Folli F.
        • Kahn C.R.
        • Hansen H.
        • Bouchie J.L.
        • Feener E.P.
        Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk.
        J Clin Invest. 1997; 100: 2158-2169
        • Sharma A.M.
        • Janke J.
        • Gorzelniak K.
        • Engeli S.
        • Luft F.C.
        Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
        Hypertension. 2002; 40: 609-611
        • Schupp M.
        • Janke J.
        • Clasen R.
        • Unger T.
        • Kintscher U.
        Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity.
        Circulation. 2004; 109: 2054-2057
        • Hermann T.S.
        • Li W.
        • Dominguez H.
        • et al.
        Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes.
        J Clin Endocrinol Metab. 2006; 91: 1001-1008
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.
        Int J Cardiol. 2008; https://doi.org/10.1016/j.ijcard.2008.11.017
        • Koh K.K.
        • Park S.M.
        • Quon M.J.
        Leptin and cardiovascular disease: response to therapeutic interventions.
        Circulation. 2008; 117: 3238-3249
        • Elliott W.J.
        • Meyer P.M.
        Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.
        Lancet. 2007; 369: 201-207
        • Azizi M.
        • Menard J.
        Combined blockade of the rennin–angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
        Circulation. 2004; 109: 2492-2499
        • Verma S.
        • Strauss M.
        Angiotensin receptor blockers and myocardial infarction.
        BMJ. 2004; 329: 1248-1249
        • Strauss M.H.
        • Hall A.S.
        Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox.
        Circulation. 2006; 114: 838-854
        • Reudelhuber T.L.
        The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous.
        Hypertension. 2005; 46: 1261-1262
        • Widdop R.E.
        • Jones E.S.
        • Hannan R.E.
        • Gaspari T.A.
        Angiotensin AT2 receptors: cardiovascular hope or hype?.
        Br J Pharmacol. 2003; 140: 809-824
        • Kim M.P.
        • Zhou M.
        • Wahl L.M.
        Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture.
        J Leukoc Biol. 2005; 78: 195-201
        • Strauss M.H.
        • Lonn E.M.
        • Verma S.
        Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists’ Collaboration.
        Eur Heart J. 2005; 26: 2351-2353
        • Verdecchia P.
        • Angeli F.
        • Gattobigio R.
        • Reboldi G.P.
        Do angiotensin II receptor blockers increase the risk of myocardial infarction?.
        Eur Heart J. 2005; 26: 2381-2386
        • McDonald M.A.
        • Simpson S.H.
        • Ezekowitz J.A.
        • Gyenes G.
        • Tsuyuki R.T.
        Angiotensin receptor blockers and risk of myocardial infarction: systematic review.
        BMJ. 2005; 331: 873
        • ONTARGET Investigators
        • Yusuf S.
        • Teo K.K.
        • et al.
        Telmisartan, ramipril, or both in patients at high risk for vascular events.
        N Engl J Med. 2008; 358: 1547-1559
        • Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with Cardiovascular Disease (TRANSCEND) Investigators
        • Yusuf S.
        • Teo K.
        • et al.
        Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
        Lancet. 2008; 372: 1174-1183
        • Han S.H.
        • Quon M.J.
        • Koh K.K.
        Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction.
        Curr Opin Lipidol. 2007; 18: 58-65
        • Muniyappa R.
        • Montagnani M.
        • Koh K.K.
        • Quon M.J.
        Cardiovascular actions of insulin.
        Endocr Rev. 2007; 28: 463-491
        • Potenza M.A.
        • Marasciulo F.L.
        • Chieppa D.M.
        • et al.
        Insulin resistance in spontaneously hypertensive rats (SHR) is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.
        Am J Physiol Heart Circ Physiol. 2005; 289: H813-H822
        • Potenza M.A.
        • Marasciulo F.L.
        • Tarquinio M.
        • Quon M.J.
        • Montagnani M.
        Treatment of spontaneously hypertensive rats (SHR) with rosiglitazone and/or enalapril simultaneously improves hypertension and insulin resistance by restoring balance between vasodilator and vasoconstrictor actions of insulin.
        Diabetes. 2006; 55: 3594-3603
        • Wei Y.
        • Whaley-Connell A.T.
        • Chen K.
        • et al.
        NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat.
        Hypertension. 2007; 50: 384-391
        • Sydow K.
        • Mondon C.E.
        • Schrader J.
        • Konishi H.
        • Cooke J.P.
        Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity.
        Arterioscler Thromb Vasc Biol. 2008; 28: 692-697
        • Laakso M.
        • Edelman S.V.
        • Brechtel G.
        • Baron A.D.
        Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanisms for insulin resistance.
        J Clin Invest. 1990; 85: 1844-1852
        • Koh K.K.
        • Son J.W.
        • Ahn J.Y.
        • et al.
        Vascular effects of diet and statin in hypercholesterolemic patients.
        Int J Cardiol. 2004; 95: 185-191
        • Nickenig G.
        • Sachinidis A.
        • Michaelsen F.
        • et al.
        Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells.
        Circulation. 1997; 95: 473-478
        • Nickenig G.
        • Bäumer A.T.
        • Temur Y.
        • et al.
        Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.
        Circulation. 1999; 100: 2131-2134
        • Bokoch G.M.
        • Prossnitz V.
        Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells.
        J Clin Invest. 1992; 89: 402-408
        • Nakagami H.
        • Jensen K.S.
        • Liao J.K.
        A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms.
        Ann Med. 2003; 35: 398-403
        • Hong H.
        • Zeng J.S.
        • Kreulen D.L.
        • Kaufman D.I.
        • Chen A.F.
        Atorvastatin protects against cerebral infarction via inhibiting NADPH oxidase-derived superoxide in ischemic stroke.
        Am J Physiol Heart Circ Physiol. 2006; 291: H2210-H2215
        • Dechend R.
        • Fiebler A.
        • Lindschau C.
        • et al.
        Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition.
        Am J Hypertens. 2001; 14: 55S-61S
        • Hauck L.
        • Harms C.
        • Grothe D.
        • et al.
        Critical role for FoxO3a-dependent regulation of p21CIP1/WAF1 in response to statin signaling in cardiac myocytes.
        Circ Res. 2007; 100: 50-60
        • Rodriguez-Porcel M.
        • Lerman L.O.
        • Herrmann J.
        • et al.
        Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function.
        Arterioscler Thromb Vasc Biol. 2003; 23: 885-891
        • Li Z.
        • Iwai M.
        • Wu L.
        • et al.
        Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
        Hypertension. 2004; 44: 758-763
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
        Circulation. 2004; 110: 3687-3692
        • Han S.H.
        • Koh K.K.
        • Quon M.J.
        • Lee Y.
        • Shin E.K.
        The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.
        Atherosclerosis. 2007; 190: 205-211
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.
        Hypertension. 2005; 45: 1088-1093
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1 + 2 in patients with type 2 diabetes.
        Atherosclerosis. 2007; 194: 230-237
        • Ceriello A.
        • Assaloni R.
        • Da Ros R.
        • et al.
        Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
        Circulation. 2005; 111: 2518-2524
        • Radaelli A.
        • Loardi C.
        • Cazzaniga M.
        • et al.
        Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
        Arterioscler Thromb Vasc Biol. 2007; 27: 2750-2755
        • Han S.H.
        • Quon M.J.
        • Koh K.K.
        Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor (PPAR)α Activators.
        Hypertension. 2005; 46: 1086-1092
        • Koh K.K.
        • Quon M.J.
        • Rosenson R.S.
        • Chung W.-J.
        • Han S.H.
        Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.
        Int J Cardiol. 2008; 124: 149-159
        • Lee H.J.
        • Choi S.S.
        • Park M.K.
        • et al.
        Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
        Biochem Biophys Res Commun. 2002; 296: 293-299
        • Choi K.C.
        • Ryu O.H.
        • Lee K.W.
        • et al.
        Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
        Biochem Biophys Res Commun. 2005; 336: 747-753
        • Ishibashi M.
        • Egashira K.
        • Hiasa K.
        • et al.
        Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
        Hypertension. 2002; 40: 687-693
        • Tao L.
        • Liu H.R.
        • Gao E.
        • et al.
        Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.
        Circulation. 2003; 108: 2805-2811
        • Hsueh W.A.
        • Bruemmer D.
        Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease.
        Hypertension. 2004; 43: 297-305
        • Calnek D.S.
        • Mazzella L.
        • Roser S.
        • Roman J.
        • Hart C.M.
        Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells.
        Arterioscler Thromb Vasc Biol. 2003; 23: 52-57
        • Hwang J.
        • Kleinhenz D.J.
        • Lassègue B.
        • et al.
        Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production.
        Am J Physiol Cell Physiol. 2005; 288: C899-905
        • Berger J.P.
        • Akiyama T.E.
        • Meinke P.T.
        PPARs: therapeutic targets for metabolic disease.
        Trends Pharmacol Sci. 2005; 26: 244-251
        • Chetty V.T.
        • Sharma A.M.
        Can PPARgamma agonists have a role in the management of obesity-related hypertension?.
        Vasc Pharmacol. 2006; 45: 46-53
        • Duan S.Z.
        • Usher M.G.
        • Mortensen R.M.
        Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
        Circ Res. 2008; 102: 283-294
        • Nicol C.J.
        • Adachi M.
        • Akiyama T.E.
        • Gonzalez F.J.
        PPARgamma in endothelial cells influences high fat diet-induced hypertension.
        Am J Hypertens. 2005; 18: 549-556
        • Tham D.M.
        • Martin-McNulty B.
        • Wang Y.X.
        • et al.
        Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.
        Physiol Genom. 2002; 11: 21-30
        • Diep Q.N.
        • Amiri F.
        • Touyz R.M.
        • et al.
        PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation.
        Hypertension. 2002; 40: 866-871
        • Sugawara A.
        • Takeuchi K.
        • Uruno A.
        • et al.
        Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells.
        Endocrinology. 2001; 142: 3125-3134
        • Van Linthout S.
        • Spillmann F.
        • Lorenz M.
        • et al.
        Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor.
        Hypertension. 2009; 53: 682-687
        • Nakamura T.
        • Yamamoto E.
        • Kataoka K.
        • et al.
        Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
        Hypertension. 2008; 51: 296-301
        • Koh K.K.
        • Han S.H.
        • Quon M.J.
        • Ahn J.Y.
        • Shin E.K.
        Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
        Diabetes Care. 2005; 28: 1419-1424
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
        Diabetes Care. 2006; 29: 195-201
        • Keech A.
        • Simes R.J.
        • Barter P.
        • et al.
        Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
        Lancet. 2005; 366: 1849-1861
        • Rosenson R.S.
        Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
        Curr Atheroscler Rep. 2006; 8: 219-222
        • Szapary P.O.
        • Bloedon L.T.
        • Samaha F.F.
        • et al.
        Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
        Arterioscler Thromb Vasc Biol. 2006; 26: 182-188
        • Sarafidis P.A.
        • Nilsson P.M.
        The effect of thiazolidinediones on blood pressure levels—a systematic review.
        Blood Press. 2006; 15: 135-150
        • Qayyum R.
        • Schulman P.
        Cardiovascular effects of the thiazolidinediones.
        Diabetes Metab Res Rev. 2006; 22: 88-97
        • Qayyum R.
        • Adomaityte J.
        A meta-analysis of the effect of thiazolidinediones on blood pressure.
        J Clin Hypertens (Greenwich). 2006; 8: 19-28
        • Suwaidi J.A.
        • Hamasaki S.
        • Higano S.T.
        • et al.
        Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.
        Circulation. 2000; 101: 948-954
        • Halcox J.P.J.
        • Schenke W.H.
        • Zalos G.
        • et al.
        Prognostic value of coronary vascular endothelial dysfunction.
        Circulation. 2002; 106: 653-658
        • Juonala M.
        • Viikari J.S.
        • Laitinen T.
        • et al.
        Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns study.
        Circulation. 2004; 110: 2918-2929
        • Halcox J.P.
        • Donald A.E.
        • Ellins E.
        • et al.
        Endothelial function predicts progression of carotid intima-media thickness.
        Circulation. 2009; 119: 1005-1012
        • Deanfield J.E.
        • Halcox J.P.
        • Rabelink T.J.
        Endothelial function and dysfunction: testing and clinical relevance.
        Circulation. 2007; 115: 1285-1295
        • Koh K.K.
        • Quon M.J.
        • Waclawiw M.A.
        Are statins effective for simultaneously treating dyslipidemias and hypertension?.
        Atherosclerois. 2008; 196: 1-8
        • Kushiro T.
        • Mizuno K.
        • Nakaya N.
        • et al.
        Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
        Hypertension. 2009; 53: 135-141
        • Williams B.
        • Lacy P.S.
        • Cruickshank J.K.
        • et al.
        Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
        Circulation. 2009; 119: 53-61
        • Sever P.S.
        • Dahlöf B.
        • Poulter N.R.
        • et al.
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
        Lancet. 2003; 361: 1149-1158
        • Demers C.
        • McMurray J.J.
        • Swedberg K.
        • et al.
        Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
        JAMA. 2005; 294: 1794-1798
        • Dahlof B.
        • Sever P.S.
        • Poulter N.R.
        • et al.
        Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        Lancet. 2005; 366: 895-906
        • Chhatriwalla A.K.
        • Nicholls S.J.
        • Wang T.H.
        • et al.
        Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
        J Am Coll Cardiol. 2009; 53: 1110-1115
        • Koh K.K.
        Combination treatment to prevent atherosclerosis.
        Hypertension. 2007; 50: e67
        • Koh K.K.
        • Quon M.J.
        Combination therapy for treatment or prevention of atherosclerosis.
        Hypertension. 2008; 52: e18
        • Koh K.K.
        • Oh P.C.
        • Quon M.J.
        Does reversal of oxidative stress and inflammation provide vascular protection?.
        Cardiovasc Res. 2009; 81: 649-659
        • Koh K.K.
        • Quon M.J.
        The importance of considering alternative or combination strategies for lowering LDL-C.
        Int J Cardiol. 2009; 136: 115-119